Growth comes from targeted therapies, backed by compelling value stories, scientific differentiation and improved patient outcomes. Kantar has the remedy.

Overview

Life sciences companies face significant disruption as the industry evolves its focus from product to value, driven by the requirement for real-world evidence and improved patient outcomes. Kantar helps you understand the market, commercialise your assets, and maximise value by delivering focused evidence and patient insights.

How we help you

  • Generate real-world evidence to demonstrate safety, effectiveness and value

    Opportunity

    Generating real-world evidence in a non-clinical setting is important to ensure your products are safe and perform as promised. With more than 30 years of experience conducting patient-centric PASS and PAES studies and partnering with industry and prescribers on international patient registries, we’ll help you to meet your real-world evidence needs.

  • Get a holistic view of patients and markets

    Opportunity

    Timely and accurate data and analytics are needed to address patient and product portfolio challenges. Our expertise for bringing together clinical data and patient-reported data, combined with our syndicated and custom research services, delivers a complete view of patients.

  • Commercialise medicines in complex and dynamic markets

    Opportunity

    Navigating brand lifecycles is complex, with little room for error. Assessing your portfolio, as well as clinical and commercial potential, understanding the market landscape, and identifying your target audience and the most effective channel for reaching them can be daunting. Kantar can help.

  • Optimise your asset to win a therapeutic category

    Opportunity

    Greater understanding, treatment development and regulatory measures are facilitating innovation in oncology and rare diseases. We bring specialised data and insights to successfully develop and commercialise your treatment.